Research Article

Muscle growth and control of production of sarcomere components

Gerry A Smith*

Published: 12 March, 2021 | Volume 6 - Issue 1 | Pages: 019-022

Here I contrast the skeletal and cardiac muscle in terms of the control muscle growth and of sarcomere component synthesis. The differences are major and reflect the long term needs of the two systems. With the skeletal system there is growth of both the number of myocytes and the sarcomere components within them dependent on demand made of the muscle. Unlike skeletal muscles the normal adult heart is greatly restricted in size, number of myocytes and their content of contractile proteins, i.e. there is little change on demand. Over time proteins get damaged or decay and for the normal heart this implies a strictly controlled maintenance synthesis of sarcomere components. From the studies of abnormal, mutated systems there is one thing inherent to and more pronounced in cardiac muscle, the FrankStarling Law of the Heart derived from the angiotensin ii type 1 receptor that my studies indicate is central to the control of sarcomere component synthesis.

Read Full Article HTML DOI: 10.29328/journal.jccm.1001111 Cite this Article Read Full Article PDF


  1. Morgan J, Partridge T. Skeletal muscle in health and disease: Disease Models & Mechanisms. 2020; 13: dmm042192. PubMed: https://pubmed.ncbi.nlm.nih.gov/32066552/
  2. Linke WA, Hamdani N. Gigantic Business: Titin Properties and Function through Thick and Thin. Circ Res. 2014; 114:1052-1068. PubMed: https://pubmed.ncbi.nlm.nih.gov/24625729/
  3. Günthel M, Barnett P, Christoffels VM. Review; Development, Proliferation, and Growth of the Mammalian Heart. Mol Ther. 2018; 26: 1599-1609. PubMed: https://pubmed.ncbi.nlm.nih.gov/29929790/
  4. Smith GA. Calcium, actomyosin kinetics, myosin binding protein-c and hypertrophic cardiomyopathy. J Integr Cardiol. 2019; 5: 1-2.
  5. Smith GA, Vandenberg JI, Freestone NS, Dixon HBF. The effect of Mg2+ on cardiac muscle function: Is CaATP the substrate for priming myofibril cross-bridge formation and Ca2+ reuptake by the sarcoplasmic reticulum? Biochem J. 2001; 354: 539-551. PubMed: https://pubmed.ncbi.nlm.nih.gov/11237858/
  6. Smith GA. The Mechanisms of Cardiac Myopathies, a kinetics approach. Leading review. J Cardiol Cardiovasc Med. 2020; 5: 141-152. PubMed: https://www.heighpubs.org/jccm/jccm-aid1101.php
  7. Smith GA. New Insights from Cardiac Muscle Applied to Skeletal Muscle. J Cardiol Cardiovasc Med. 2021; 6: 007-013. PubMed: https://www.heighpubs.org/jccm/jccm-aid1109.php
  8. Doggrell SA. Losartan for LIFE in hypertension with left ventricular hypertrophy? Expert Opin Pharmacother. 2003; 4: 115-118. PubMed: https://pubmed.ncbi.nlm.nih.gov/12517248/
  9. Smith GA. The Mechanisms of the Frank-Starling Law and Familial Cardiomyopathy are Different. The Function of Myosin Binding Protein-C is Retained on Myocyte Length Increase and Force Generated is Kinase controlled. J Integr Cardiol. 2019; 5: 13.
  10. Katz AM. Ernest Henry Starling, His Predecessors, and the "Law of the Heart". Circulation. 2002; 106: 2986–2992. PubMed: https://pubmed.ncbi.nlm.nih.gov/12460884/
  11. Abraham DM, Davis RT, Warren CM, Mao L, Wolska BM, et al. β-Arrestin mediates the Frank–Starling mechanism of cardiac contractility. PNAS. 2016; 113: 14426–14431. PubMed: https://pubmed.ncbi.nlm.nih.gov/27911784/
  12. Smith GA. Angiotensin II type 1 receptor and the activation of Myosin LightChain Kinase and Protein Kinase C-βII: Mini Review. J Cardiol Cardiovasc Med. 2020; 5: 024-028. PubMed: https://www.heighpubs.org/jccm/jccm-aid1081.php
  13. Hoshikawa E, Matsumura Y, Kubo T, Okawa M, Yamasaki N, et al. Effect of Left Ventricular Reverse Remodeling on Long-TermPrognosis After Therapy With Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers and β Blockers in Patients With Idiopathic Dilated Cardiomyopathy. Am J Cardiol. 2011; 107: 1065–1070. PubMed: https://pubmed.ncbi.nlm.nih.gov/21296328/
  14. Losartan Potassium 25 mg film coated tablets, Last updated on emc: 13 Mar 2020. Datapharm. The electronic medicines compendium (emc). PubMed: https://www.medicines.org.uk/emc/product/8735/smpc
  15. Goette A, Lendeckel U. Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms. Europace. 2008; 10: 238– 241. PubMed: https://pubmed.ncbi.nlm.nih.gov/18256129/
  16. Seguchi O, Takashima S, Yamazaki S, Asakura M, Asano Y, et al. A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. J Clin Invest. 2007; 117: 2812–2824. PubMed: https://pubmed.ncbi.nlm.nih.gov/17885681/
  17. Kampourakis T, Suna YB. Irving M. Myosin light chain phosphorylation enhances contraction of heart muscle via structural changes in both thick and thin filaments. PNAS. 2016; E3039–E3047. PubMed: https://pubmed.ncbi.nlm.nih.gov/27162358/
  18. Massengill MT, Ashrafm HM, Chowdhury RR, Chrzanowski SM, Kar J, et al. Acute heart failure with cardiomyocyte atrophy induced in adult mice by ablation of cardiac myosin light chain kinase. Cardiovasc Res. 2016; 111: 34–43. PubMed: https://pubmed.ncbi.nlm.nih.gov/27025239/


Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More